Key Information
High-risk groups:
- Females ≥65, males ≥75
- Women 50-64, men 50-74 with risk factors
- <50 with previous fragility fractures, untreated premature menopause, frequent corticosteroid use
- <40 with multiple fragility fractures, frequent corticosteroid use
- Taking SSRIs, antipsychotics, PPIs, aromatase inhibitors, GnRH agonists, thiazolidinediones
- Review bisphosphonates every 3-5 years
- Max treatment duration: Alendronic acid 10 years, risedronate 7 years
- Avoid bisphosphonates & calcichew in CKD stages 3-4